Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether Degarelix is associated with less endothelial
dysfunction (an intermediate in the development of cardiac disease) and cardiovascular
biomarkers compared to LHRH agonists.